Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death amongst gynecological cancers. Due to the nonspecific nature of disease symptoms, the majority of ovarian cancer patients are diagnosed with advanced-stage disease, at which point the prognosis is poor. Current standard of care therapies focus on debulking surgery and platinum-based chemotherapy, with carboplatin and paclitaxel being the gold standard. The majority of patients respond well to initial first-line therapy and enter into remission, however over 80% of patients will relapse and require multiple lines of therapy.
For many years the ovarian cancer drug market has been fairly stagnant, mainly due to the high use of generics and the lack of successful development of new innovative therapies. However, with the recent approvals of Avastin and the PARP inhibitors Lynparza (olaparib), Rubraca (rucaparib), and Zejula (niraparib), the market is beginning to diversify. New understanding of the heterogeneity and biology of ovarian cancer has led to the active development of new targeted therapies, immuno-oncology (IO) drugs, and next-generation chemotherapies. A greater understanding of the tumor microenvironment is expected to occur over the forecast period, which is anticipated to further drive the successful development of new patient-specific therapies. Research is predicting a total of 9 new entrants to launch over the forecast period from 2015-2025. Competition will be particularly fierce amongst PARP inhibitors as they continue to establish their place in the treatment paradigm of ovarian cancer.
Key Questions Answered
~ How will the ovarian cancer market landscape in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) change from 2015–2025?
~ What are the most promising late-stage pipeline drugs in ovarian cancer?
~ How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
~ What are the unmet needs in ovarian cancer treatment management?
~ What drivers and barriers will affect ovarian cancer therapeutics sales in the 7MM over the forecast period?
~ Overview of ovarian cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
~ Topline ovarian cancer market revenue from 2015–2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
~ Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting ovarian cancer therapeutics sales in the 7MM.
~ Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
~ Analysis of the current and future market competition in the 7MM ovarian cancer therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to:
~ Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
~ Develop business strategies by understanding the trends shaping and driving the 7MM ovarian cancer therapeutics market.
~ Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the ovarian cancer therapeutics market in the future.
~ Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
~ Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
~ Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Innate Pharma …
Pages: 280 Published: May’ 2017 Format: Electronic PDF Pricing: $10,995 (Single User)
To procure a copy or for more info, please feel free to Contact Us